Earnings call Cipla reported its highest-ever quarterly revenue of ₹7,589 crore in Q2 FY26, up 8% YoY, with a robust EBITDA margin of 25%. Growth was broad-based across India, U.S., and Europe, with ...

CHENNAI: India's fourth largest drug maker by revenue Cipla Ltd posted a steady performance for the September quarter, reporting a 4 percent year-on-year rise in consolidated net profit to Rs 1,351 ...

The respiratory medication sales outpaced the market in December 2025, with volumes growing roughly twice as fast as the broader Indian pharmaceutical market (IPM) led by seasonal factors, ...